Loading...

We've got a brand new version of Simply Wall St! Try it out

Leviathan Cannabis Group

CNSX:EPIC
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EPIC
CNSX
CA$35M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Leviathan Cannabis Group Inc., through its subsidiaries, operates as a marketing services agency company in the cannabis sector in Canada and internationally. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
EPIC Share Price and Events
7 Day Returns
26.2%
CNSX:EPIC
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-67.2%
CNSX:EPIC
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
EPIC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Leviathan Cannabis Group (EPIC) 26.2% 54.7% 9.3% -67.2% 8100% 241.7%
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • EPIC underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • EPIC underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
EPIC
Industry
5yr Volatility vs Market

EPIC Value

 Is Leviathan Cannabis Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Leviathan Cannabis Group. This is due to cash flow or dividend data being unavailable. The share price is CA$0.41.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Leviathan Cannabis Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Leviathan Cannabis Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:EPIC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in CAD CA$-0.07
CNSX:EPIC Share Price ** CNSX (2019-09-20) in CAD CA$0.41
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Leviathan Cannabis Group.

CNSX:EPIC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:EPIC Share Price ÷ EPS (both in CAD)

= 0.41 ÷ -0.07

-5.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Leviathan Cannabis Group is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Leviathan Cannabis Group is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Leviathan Cannabis Group's expected growth come at a high price?
Raw Data
CNSX:EPIC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Leviathan Cannabis Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Leviathan Cannabis Group's assets?
Raw Data
CNSX:EPIC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in CAD CA$0.43
CNSX:EPIC Share Price * CNSX (2019-09-20) in CAD CA$0.41
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:EPIC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:EPIC Share Price ÷ Book Value per Share (both in CAD)

= 0.41 ÷ 0.43

0.96x

* Primary Listing of Leviathan Cannabis Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Leviathan Cannabis Group is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Leviathan Cannabis Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Leviathan Cannabis Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

EPIC Future Performance

 How is Leviathan Cannabis Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Leviathan Cannabis Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Leviathan Cannabis Group expected to grow at an attractive rate?
  • Unable to compare Leviathan Cannabis Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Leviathan Cannabis Group's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Leviathan Cannabis Group's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:EPIC Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:EPIC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:EPIC Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-05-31 0 -3 -6
2019-02-28 0 -2 -8
2018-11-30 0 -2 -7
2018-08-31 0 -1 -6
2018-05-31 0 0 -2
2018-02-28 0 0 0
2017-11-30 0 0
2017-08-31 0 0
2017-05-31 0 0
2017-02-28 0 0
2016-11-30 0 0
2016-08-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Leviathan Cannabis Group is high growth as no earnings estimate data is available.
  • Unable to determine if Leviathan Cannabis Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:EPIC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Leviathan Cannabis Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:EPIC Past Financials Data
Date (Data in CAD Millions) EPS *
2019-05-31 -0.07
2019-02-28 -0.11
2018-11-30 -0.11
2018-08-31 -0.13
2018-05-31 -0.05
2018-02-28 0.00
2017-11-30 0.00
2017-08-31 0.00
2017-05-31 0.00
2017-02-28 0.00
2016-11-30 0.00
2016-08-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Leviathan Cannabis Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of EPIC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Leviathan Cannabis Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Leviathan Cannabis Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Leviathan Cannabis Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Leviathan Cannabis Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

EPIC Past Performance

  How has Leviathan Cannabis Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Leviathan Cannabis Group's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Leviathan Cannabis Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Leviathan Cannabis Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Leviathan Cannabis Group's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Leviathan Cannabis Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Leviathan Cannabis Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:EPIC Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 0.14 -6.24 6.44
2019-02-28 0.16 -8.30 7.74
2018-11-30 0.14 -7.35 7.02
2018-08-31 0.08 -6.38 6.32
2018-05-31 0.02 -2.21 2.23
2018-02-28 0.00 -0.18 0.13
2017-11-30 -0.07 0.07
2017-08-31 -0.06 0.06
2017-05-31 -0.06 0.06
2017-02-28 -0.06 0.06
2016-11-30 -0.07 0.07
2016-08-31 -0.05 0.05
2016-05-31 -0.76 0.11
2016-02-29 -1.35 0.17
2015-11-30 -1.43 0.25
2015-08-31 -1.47 0.32
2015-05-31 -0.90 0.48
2015-02-28 -0.37 0.48
2014-11-30 -2.03 0.44
2014-08-31 -2.04 0.42
2013-08-31 -0.24 0.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Leviathan Cannabis Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Leviathan Cannabis Group has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Leviathan Cannabis Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Leviathan Cannabis Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Leviathan Cannabis Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

EPIC Health

 How is Leviathan Cannabis Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Leviathan Cannabis Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Leviathan Cannabis Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Leviathan Cannabis Group's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Leviathan Cannabis Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Leviathan Cannabis Group Company Filings, last reported 3 months ago.

CNSX:EPIC Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 40.34 3.63 1.88
2019-02-28 40.26 3.61 2.76
2018-11-30 41.17 3.55 3.49
2018-08-31 40.00 3.45 2.87
2018-05-31 1.29 0.00 0.04
2018-02-28 1.47 0.00 0.06
2017-11-30 -0.23 0.02 0.03
2017-08-31 -0.20 0.00 0.02
2017-05-31 -0.19 0.00 0.02
2017-02-28 -0.18 0.00 0.02
2016-11-30 -0.16 0.00 0.03
2016-08-31 -0.14 0.00 0.05
2016-05-31 -0.13 0.00 0.05
2016-02-29 -0.12 0.00 0.07
2015-11-30 -0.10 0.00 0.01
2015-08-31 -0.09 0.00 0.03
2015-05-31 0.55 0.00 0.05
2015-02-28 1.15 0.00 0.13
2014-11-30 1.13 0.00 0.36
2014-08-31 1.05 0.00 0.50
2013-08-31 0.25 0.00 0.07
  • Leviathan Cannabis Group's level of debt (9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Leviathan Cannabis Group's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Leviathan Cannabis Group has less than a year of cash runway based on current free cash flow.
  • Leviathan Cannabis Group has less than a year of cash runway if free cash flow continues to grow at historical rates of 135.8% each year.
X
Financial health checks
We assess Leviathan Cannabis Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Leviathan Cannabis Group has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

EPIC Dividends

 What is Leviathan Cannabis Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Leviathan Cannabis Group dividends.
If you bought CA$2,000 of Leviathan Cannabis Group shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Leviathan Cannabis Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Leviathan Cannabis Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:EPIC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Leviathan Cannabis Group has not reported any payouts.
  • Unable to verify if Leviathan Cannabis Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Leviathan Cannabis Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Leviathan Cannabis Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Leviathan Cannabis Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Leviathan Cannabis Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Leviathan Cannabis Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

EPIC Management

 What is the CEO of Leviathan Cannabis Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Martin Doane
COMPENSATION CA$1,499,022
TENURE AS CEO 1.3 years
CEO Bio

Mr. Martin J. Doane has been Chief Executive Officer and Director of Leviathan Cannabis Group Inc. (Also known as Morgan Resources Corp) since June 4, 2018 and June 05, 2018 respectively and serves as its Chairman. Mr. Doane served as Interim Chief Financial Officer of Leviathan Cannabis Group Inc. from February 21, 2019 to April 2019. He has 27 years' experience as a lawyer and 20 years of concentrated activity in the capital markets and business executive ranks in Canada, the U.S. and Europe. Mr. Doane also has extensive experience and expertise in the North American cannabis sector. For the last three years, he has served as the Managing Director of Brand Canna Growth Partners. As part of his responsibilities at BCGP, he was instrumental in financing, building and managing Santé Veritas Holdings, which is at the final stage of obtaining a cultivation license from Health Canada. During his legal career, Mr. Doane has been a partner at Gowlings, a founder, Partner at Paliare Roland and a Founder and Chairman of Doane, Phillips & Young, Barristers. He has engaged in a diverse litigation practice, involving significant work in the areas of corporate, employment, constitutional, securities, human rights and class action litigation. He appeared as counsel at all levels of court in Canada and has dozens of reported decisions to his credit. Always active in the pro bono sphere, Mr. Doane litigated numerous precedent-setting cases as Special Counsel for the Canadian Civil Liberties Association and Democracy Watch. He is a graduate of the University of Western Ontario and Osgoode Hall Law School. He is a recipient of the Golden Jubilee Medal awarded for his contribution to Canadian law in the area of the provision and management of police services.

CEO Compensation
  • Insufficient data for Martin to compare compensation growth.
  • Martin's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Leviathan Cannabis Group management team in years:

0.8
Average Tenure
  • The average tenure for the Leviathan Cannabis Group management team is less than 2 years, this suggests a new team.
Management Team

Martin Doane

TITLE
Chairman & CEO
COMPENSATION
CA$1M
TENURE
1.3 yrs

Jayne Beckwith

TITLE
Interim CFO & Chief Communications Officer
COMPENSATION
CA$98K
TENURE
0.4 yrs

Luvlina Sanghera

TITLE
Chief Marketing Officer
TENURE
0.5 yrs

Dan Grady

TITLE
Head of Production
TENURE
1 yrs
Board of Directors

Martin Doane

TITLE
Chairman & CEO
COMPENSATION
CA$1M

R. Jarvis

TITLE
Independent Director
TENURE
0.8 yrs

Matthew Brace

TITLE
Independent Director
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
21. May 19 Buy Jiansong Gong Individual 03. May 19 03. May 19 15,000,000 CA$0.15 CA$2,250,000
09. May 19 Sell Joseph Bidinot Individual 03. May 19 03. May 19 -10,000,000 CA$0.15 CA$-1,500,000
08. May 19 Sell Renny Bidinot Individual 03. May 19 03. May 19 -10,000,000 CA$0.10 CA$-1,000,004
X
Management checks
We assess Leviathan Cannabis Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Leviathan Cannabis Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

EPIC News

Simply Wall St News

Who Are The Largest Shareholders In Leviathan Cannabis Group Inc (CNSX:EPIC)?

In this article, I will take a quick look at Leviathan Cannabis Group Inc’s (CNSX:EPIC) recent ownership structure – an unconventional investing subject, but an important one. … Ownership structure of a company has been found to affect share performance over time. … Check out our latest analysis for Leviathan Cannabis Group

Simply Wall St -

EPIC Company Info

Description

Leviathan Cannabis Group Inc., through its subsidiaries, operates as a marketing services agency company in the cannabis sector in Canada and internationally. It also owns and operates a greenhouse production facility in Pelham, Ontario. The company was formerly known as Morgan Resources Corp. and changed its name to Leviathan Cannabis Group Inc. in April 2018. Leviathan Cannabis Group Inc. is headquartered in Toronto, Canada.

Details
Name: Leviathan Cannabis Group Inc.
EPIC
Exchange: CNSX
Founded:
CA$34,744,877
84,743,603
Website: http://leviathancannabis.com
Address: Leviathan Cannabis Group Inc.
250 The Esplanade,
Suite 116,
Toronto,
Ontario, M5A 4J6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX EPIC Common Shares Canadian National Stock Exchange CA CAD 13. Jan 2014
OTCPK LVCN.F Common Shares Pink Sheets LLC US USD 13. Jan 2014
Number of employees
Current staff
Staff numbers
0
Leviathan Cannabis Group employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:47
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/29
Last earnings reported: 2019/05/31
Last annual earnings reported: 2018/08/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.